AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 293 min read$VNDA

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Vanda Pharmaceuticals (VNDA) reported positive Phase III results for HETLIOZ® in treating Delayed Sleep-Wake Phase Disorder. The study showed a 37.1-minute earlier sleep onset vs. placebo. Vanda plans to submit an sNDA for this new indication, aiming to make HETLIOZ® the first FDA-approved treatment for the disorder.

Original reporting
prnewswire.com
Published Sep 29, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 10:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder — source image
Source · prnewswire.com
Decision brief

The 30-second read

$VNDABullishMed
01

Why it matters

The data provide a clear efficacy signal (37.1‑minute earlier sleep onset vs placebo) and may lead to a supplemental NDA filing, which historically moves biotech stocks.

02

Market read

Positive trial data for a niche sleep disorder could expand Vanda's addressable market and drive near‑term stock movement.

03

What to watch

Potential competition from other melatonin agonists and the small trial size may temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Vanda Pharmaceuticals (NASDAQ: VNDA) currently markets HETLIOZ® for Non‑24‑Hour Sleep‑Wake Disorder and Smith‑Magenis Syndrome. The Phase III trial adds Delayed Sleep‑Wake Phase Disorder as a potential new indication.

Company-level read

Ticker impact

$VNDABullishHigh confidence
Context

Vanda Pharmaceuticals announced positive Phase III topline results for HETLIOZ® in Delayed Sleep-Wake Phase Disorder, a new indication that could drive FDA approval.

Expected impact

upside pressure as investors price in a probable regulatory approval and expanded market opportunity.

Evidence & confidence

Phase III success is a material catalyst for biotech stocks; market typically reacts positively to new indication data.

Market effects

Sector

May broaden the circadian‑regulator niche and support other sleep‑disorder therapeutics.

Regional

U.S. biotech sector could see modest gains on the news.

Global

Limited to investors tracking sleep‑disorder drug pipelines.

Counterpoint

What could challenge this read

If FDA delays or requires additional data, the initial rally could reverse.

Key entities

  • company
    Vanda Pharmaceuticals Inc.

    Developer of HETLIOZ® and issuer of the press release.

  • executive
    Mihael H. Polymeropoulos, M.D.

    President, CEO and Chairman of Vanda, quoted in the release.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 16
$VNDAHighAI 8/10

Vanda Pharmaceuticals’ VQW-765 misses primary endpoint

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after hours as its Phase III trial for VQW-765 failed to meet the primary endpoint in treating acute anxiety in adults with social anxiety disorder. The study was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 30 U.S. sites.

thepharmaletter.com1 min
OCT 15
$VNDAMedAI 8/10

Phase 3 Trial of VQW-765 for Social Anxiety Disorder Misses Endpoint

Vanda Pharmaceuticals' phase 3 trial for VQW-765, an investigational treatment for social anxiety disorder, missed its primary endpoint. The study showed no significant difference in distress levels between participants receiving VQW-765 and those receiving a placebo. The company is evaluating the data, and the clinical program is currently on hold.

empr.com4 min
OCT 15
$VNDAMed

Vanda freezes Novartis-originated social anxiety program after late-stage disappointment

Vanda Pharmaceuticals halted development of VQW-765, a social anxiety drug licensed from Novartis, after it failed to show significant benefit in a late-stage study. The Phase 3 trial, focused on female participants, showed no distress reduction versus placebo. Vanda will analyze the full dataset before deciding next steps. Oppenheimer analysts noted this was a clean miss but do not expect it to significantly impact their estimates for Vanda.

biospace.com5 min
OCT 15
$VNDAHighAI 8/10

Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phas

Vanda Pharmaceuticals (VNDA) shares fell 2% premarket after its Phase III trial for anxiety drug VQW-765 failed to meet primary and key secondary endpoints. The company paused the program for further analysis, confirming the drug's safety. VNDA's P/S ratio is 1.16, below historical and industry medians, reflecting market skepticism. Insider selling totaled $2.8M, with mixed institutional sentiment.

gurufocus.com2 min
OCT 14
$VNDAHighAI 8/10

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after its anxiety drug VQW-765 failed to meet the primary endpoint in a Phase III trial. The study did not show statistical significance in reducing distress levels in female participants with social anxiety disorder. The company plans to analyze the full dataset before deciding on next steps. VQW-765 was licensed from Novartis and is being developed for psychiatric disorders.

investing.com2 min